» Articles » PMID: 39478210

Tumour Evolution and Microenvironment Interactions in 2D and 3D Space

Abstract

To study the spatial interactions among cancer and non-cancer cells, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics (ST). This was combined with 48 matched single-nucleus RNA sequencing samples and 22 matched co-detection by indexing (CODEX) samples. To describe tumour structures and habitats, we defined 'tumour microregions' as spatially distinct cancer cell clusters separated by stromal components. They varied in size and density among cancer types, with the largest microregions observed in metastatic samples. We further grouped microregions with shared genetic alterations into 'spatial subclones'. Thirty five tumour sections exhibited subclonal structures. Spatial subclones with distinct copy number variations and mutations displayed differential oncogenic activities. We identified increased metabolic activity at the centre and increased antigen presentation along the leading edges of microregions. We also observed variable T cell infiltrations within microregions and macrophages predominantly residing at tumour boundaries. We reconstructed 3D tumour structures by co-registering 48 serial ST sections from 16 samples, which provided insights into the spatial organization and heterogeneity of tumours. Additionally, using an unsupervised deep-learning algorithm and integrating ST and CODEX data, we identified both immune hot and cold neighbourhoods and enhanced immune exhaustion markers surrounding the 3D subclones. These findings contribute to the understanding of spatial tumour evolution through interactions with the local microenvironment in 2D and 3D space, providing valuable insights into tumour biology.

Citing Articles

Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments.

Jing S, Wang H, Lin P, Yuan J, Tang Z, Li H NPJ Precis Oncol. 2025; 9(1):68.

PMID: 40069556 PMC: 11897387. DOI: 10.1038/s41698-025-00857-1.


Liver Metastasis in Cancer: Molecular Mechanisms and Management.

Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J MedComm (2020). 2025; 6(3):e70119.

PMID: 40027151 PMC: 11868442. DOI: 10.1002/mco2.70119.


Crosstalk Between H-Type Vascular Endothelial Cells and Macrophages: A Potential Regulator of Bone Homeostasis.

Fan J, Xie Y, Liu D, Cui R, Zhang W, Shen M J Inflamm Res. 2025; 18:2743-2765.

PMID: 40026304 PMC: 11871946. DOI: 10.2147/JIR.S502604.


The clinical application of artificial intelligence in cancer precision treatment.

Wang J, Zeng Z, Li Z, Liu G, Zhang S, Luo C J Transl Med. 2025; 23(1):120.

PMID: 39871340 PMC: 11773911. DOI: 10.1186/s12967-025-06139-5.

References
1.
Fu T, Dai L, Wu S, Xiao Y, Ma D, Jiang Y . Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021; 14(1):98. PMC: 8234625. DOI: 10.1186/s13045-021-01103-4. View

2.
Schmitt M, Loeb L, Salk J . The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2015; 13(6):335-47. PMC: 4838548. DOI: 10.1038/nrclinonc.2015.175. View

3.
Roper N, Brown A, Wei J, Pack S, Trindade C, Kim C . Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020; 1(1). PMC: 7263628. DOI: 10.1016/j.xcrm.2020.100007. View

4.
Tredan O, Galmarini C, Patel K, Tannock I . Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99(19):1441-54. DOI: 10.1093/jnci/djm135. View

5.
Qu Y, Dou B, Tan H, Feng Y, Wang N, Wang D . Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019; 18(1):69. PMC: 6441162. DOI: 10.1186/s12943-019-0992-4. View